COSCIENS Biopharma Inc.
CSCI.TO
TSX
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 66.47% | 6.91% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 66.47% | 6.91% | |||
| Cost of Revenue | 28.40% | -5.36% | |||
| Gross Profit | 119.04% | 30.21% | |||
| SG&A Expenses | -12.18% | -43.83% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 3.93% | -36.98% | |||
| Operating Income | 157.81% | 69.43% | |||
| Income Before Tax | -10.38% | 91.58% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -10.38% | 91.62% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -101.88% | 592.76% | |||
| EBIT | 157.81% | 69.43% | |||
| EBITDA | 295.12% | 91.28% | |||
| EPS Basic | -101.88% | 599.35% | |||
| Normalized Basic EPS | -10.44% | 91.47% | |||
| EPS Diluted | -101.88% | 599.10% | |||
| Normalized Diluted EPS | -10.44% | 91.47% | |||
| Average Basic Shares Outstanding | 0.02% | -1.32% | |||
| Average Diluted Shares Outstanding | 0.02% | -1.32% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||